Macromolecules
Article
vector.9 Rationally designed functionalities of the micelle core
are expected to enhance the overall performance of micelle
nanocarriers by tuning the drug loading capacity, stability, and
“smartness”.10−12,25,26 Previously, we employed an octyloxy
substituent attached to the γ-position of the ε-caprolactone to
form the micelle core. However, only moderate drug loading
and stability were achieved. To further optimize this class of
amphiphilic thermoresponsive polycaprolactone block copoly-
mers as drug carriers and systematically study the substituent
effect on the micellar assembly, we synthesized five
polycaprolactone amphiphilic block copolymers with different
hydrophobic substituents. Octyloxy, ethylhexyloxy, ethoxy,
benzyloxy, and cyclohexylmethoxy were used as substituents
on the core-forming block. The substituents were chosen to
compare linear vs branched aliphatic substituents, long vs short
aliphatic substituents, and aromatic vs nonaromatic ring
substituents. These functionalities on the core segment were
expected to interact intra- and intermolecularly with the
encapsulated drug molecules by noncovalent interactions,
such as hydrophobic, π−π stacking, and hydrogen bonding.
Doxorubicin (DOX) was employed as a model drug as its
interactions with polymer chains govern the encapsulation
behavior by polymeric micelles.12 In summary, the substituent
effect on thermal-induced phase transition, thermodynamic and
kinetic stability, drug loading, and thermo-induced drug release
of DOX were investigated for this library of polycaprolactone
amphiphilic block copolymers.
rate = 1.0 mL/min, injector volume = 100 μL, detector temperature =
30 °C, and column temperature = 35 °C. All the polymers samples
were dissolved in THF, and the solutions were filtered through PTFE
filters (0.45 μm) prior to injection.
General Procedure for the Synthesis of Amphiphilic Diblock
Copolymers P1−P5. All the monomers were dried by azeotropic
distillation from toluene before the reaction. Dried γ-2-[2-(2-
methoxyethoxy)ethoxy]ethoxy-ε-caprolactone (0.5 g, 1.8 × 10−3
mol) was transferred into a flame-dried 10 mL Schlenk flask under a
nitrogen atmosphere. Stock solutions of Sn(Oct)2 (0.016 g, 3.6 × 10−5
mol) in hexane and benzyl alcohol (0.004g, 3.6 × 10−5 mol) in hexane
were added to the Schlenk flask under a nitrogen atmosphere. The
reaction mixture was deoxygenated by three consecutive freeze−
pump−thaw cycles, and the vacuum of the last cycle was canceled with
nitrogen. The reaction flask was heated in a thermostated oil bath at
110 °C for 4 h. At this time a sample was collected to determine the
monomer conversion and molecular weight by 1H NMR analysis.
Deoxygenated monomers (M1−M5) (1.8 × 10−3 mol) were added to
the reaction flask under a nitrogen atmosphere, and the reaction was
left overnight at 110 °C.
Poly{γ-2-[2-(2-methoxyethoxy)ethoxy]ethoxy-ε-caprolactone}-b-
1
poly(γ-octyloxy-ε-caprolactone) (P1). H NMR (500 MHz, CDCl3):
δH 0.89 (t, 3H), 1.27 (m, 10H), 1.54 (m, 2H), 1.80 (m, 8H), 2.38 (m,
4H), 3.38 (m, 6H), 3.60 (m, 13H), 4.15 (m, 4H) (the polymer
contains 53.5% PMEEE).
Poly{γ-2-[2-(2-methoxyethoxy)ethoxy]ethoxy-ε-caprolactone}-b-
1
poly[γ-(2-ethylhexyloxy)-ε-caprolactone] (P2). H NMR (500 MHz,
CDCl3): δH 0.87 (m, 6H), 1.27 (m, 9H), 1.80 (m, 8H), 2.37 (m, 4H),
3.38 (m, 3H), 3.60 (m, 16H), 4.16 (b, 4H) (the polymer contains
54.1% PMEEE).
Poly{γ-2-[2-(2-methoxyethoxy)ethoxy]ethoxy-ε-caprolactone}-b-
poly(γ-ethoxy-ε-caprolactone) (P3). 1H NMR (500 MHz, CDCl3): δH
1.17 (t, 3H), 1.8 (m, 8H), 2.39 (m, 4H), 3.38 (s, 3H), 3.47 (m, 3H),
3.59 (m, 13H), 4.17 (t, 4H) (the polymer contains 62.8% PMEEE).
Poly{γ-2-[2-(2-methoxyethoxy)ethoxy]ethoxy-ε-caprolactone}-b-
poly(γ-benzyloxy-ε-caprolactone) (P4). 1H NMR (500 MHz, CDCl3):
δH 1.80 (m, 8H), 2.37 (m, 4H), 3.38 (s, 3H), 3.59 (m, 14H), 4.15 (b,
4H), 4.47 (m, 2H), 7.30 (b, 5H) (the polymer contains 54.4%
PMEEE).
Poly{γ-2-[2-(2-methoxyethoxy)ethoxy]ethoxy-ε-caprolactone}-b-
poly(γ-cyclohexylmethoxy-ε-caprolactone) (P5). 1H NMR (500 MHz,
CDCl3): δH 0.93 (m, 2H), 1.24 (m, 3H), 1.81 (m, 14H), 2.40 (m,
4H), 3.22 (m, 2H), 3.40 (s, 3H), 3.62 (m, 14H), 4.18 (m, 4H) (the
polymer contains 53.4% PMEEE).
Preparation of Polymeric Micelles and Drug Encapsulation.
Each polymer (20 mg) was dissolved in 1 mL of THF, and 40 μL of
the polymer THF solution was added dropwise to 4 mL of deionized
water under vigorous agitation. THF was removed by dialyzing the
mixture against deionized water for 1 day (MWCO = 3 kDa). The
micelle suspension was filtered through a 0.45 μm filter before
characterization. Doxorubicin (DOX) was encapsulated in polymeric
micelles as a model hydrophobic guest molecule. DOX was first
treated with 3 equiv of triethylamine in DMSO. The neutralized DOX
solution was mixed with each polymer THF solution at a mass ratio of
1:10. The polymer/DOX mixture (40 μL) was added dropwise to 4
mL of deionized water under vigorous agitation. The DOX-loaded
micelle suspension was dialyzed against deionized water for 1 day and
then filtered with a 0.45 μm filter before characterization. Equivalent
DOX concentration in the micelles was determined by fitting readout
absorbance of DOX loaded micelles at 485 nm to a pre-established
standard curve of DOX. Loading efficiency (LE) and loading capacity
(LC) of all polymeric micelles, assuming there was no loss of polymer
during sample preparation, were calculated according to the following
equations:
In addition to exploring the substituent effect experimentally,
we were also interested in whether the micellar behavior can be
predicted by molecular dynamics (MD) simulation. While
molecular dynamics has been applied to study micellation
behavior,27,28 this is the first report of using MD methodology
to study the substituent effect of polymeric micelles. MD
simulations were performed for micelles with the same polymer
backbone and similar functional hydrophobic substituents as
the experimentally synthesized polymers. The drug loading
behavior was predicted by using phenol as a DOX alternative.
The free volume of the micellar core was calculated for both
drug loaded and unloaded micelles. The results indicated that
the interaction between the drug and polymer is more
important than the void volume of the micelle cores in
determining the drug loading capacity (DLC).
MATERIALS AND METHODS
■
Materials and Characterization. All commercial chemicals were
purchased from Aldrich Chemical Co., Inc., and were used without
further purification unless otherwise noted. Stannous(II) 2-ethyl-
hexanoate was purified by vacuum distillation prior to use. γ-Octyloxy-
ε-caprolactone and γ-2-[2-(2-methoxyethoxy)ethoxy]ethoxy-ε-capro-
lactone monomers were synthesized according to the previously
reported procedure.14
1H NMR spectra of the synthesized monomers and polymers were
1
recorded on a Bruker 500 MHz spectrometer at 30 °C in CDCl3. H
NMR data are reported in parts per million as chemical shift relative to
tetramethylsilane (TMS) as the internal standard. GC/MS was
performed on an Agilent 6890-5973 GC-MS workstation. The
following conditions were used for all GC/MS analyses: injector and
detector temperature, 250 °C; initial temperature, 70 °C; temperature
ramp, 10 °C/min; final temperature, 280 °C. Molecular weights of the
synthesized polymers were measured by size exclusion chromatog-
raphy (SEC) analysis on a Viscotek VE 3580 system equipped with
ViscoGEL columns (GMHHR-M), connected to a refractive index
(RI) detector. GPC solvent/sample module (GPCmax) was used with
HPLC grade THF as the eluent, and calibration was based on
polystyrene standards. Running conditions for SEC analysis were flow
weight of encapsulated DOX
LE (wt %) =
LC (wt %) =
× 100%
× 100%
weight of total DOX
weight of encapsulated DOX
weight of polymer
B
dx.doi.org/10.1021/ma400855z | Macromolecules XXXX, XXX, XXX−XXX